Assessment and Treatment of Anxiety Disorders in Children and Adolescents

  • Anna M. Wehry
  • Katja Beesdo-Baum
  • Meghann M. Hennelly
  • Sucheta D. Connolly
  • Jeffrey R. StrawnEmail author
Child and Adolescent Disorders (T Benton, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Child and Adolescent Disorders


Recent advances in the developmental epidemiology, neurobiology, and treatment of pediatric anxiety disorders have increased our understanding of these conditions and herald improved outcomes for affected children and adolescents. This article reviews the current epidemiology, longitudinal trajectory, and neurobiology of anxiety disorders in youth. Additionally, we summarize the current evidence for both psychotherapeutic and psychopharmacologic treatments of fear-based anxiety disorders (e.g., generalized, social, and separation anxiety disorders) in children and adolescents. Current data suggest that these disorders begin in childhood and adolescence, exhibit homotypic continuity, and increase the risk of secondary anxiety and mood disorders. Psychopharmacologic trials involving selective serotonin reuptake inhibitors (SSRIs) and selective serotonin norepinephrine reuptake inhibitors (SSNRIs) are effective in pediatric patients with anxiety disorders and have generally demonstrated moderate effect sizes. Additionally, current data support cognitive behavioral therapy (CBT) for the treatment of these conditions in youth and suggest that the combination of psychotherapy + an SSRI may be associated with greater improvement than would be expected with either treatment as monotherapy.


Antidepressant Anxiety disorders 



Selective serotonin reuptake inhibitor


Separation anxiety disorder


Social phobia


Generalized anxiety disorder


Compliance with Ethics Guidelines

Conflict of Interest

Katja Beesdo-Baum and Meghann M. Hennelly declare that they have no conflict of interest.

Anna M. Wehry has received a grant from the American Academy of Child and Adolescent Psychiatry.

Sucheta D. Connolly has received a grant from the National Institute of Mental Health, 1R01MH086517, (01 Jul. 2010–31 Mar. 2015) (Phan and Monk, co-PIs) Brain Markers of Anxiety Disorders and SSRI Treatment in Children and Adolescents. Role: coinvestigator.

Jeffrey R. Strawn has received research support from Edgemont, Eli Lilly, Shire, Forest Research Institute and the National Institute of Mental Health (NIMH).

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21(3):169–84.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Merikangas KR, He JP, Burnstein M, Swanson SA, Avenevoli S, Cui L, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication—Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010;49(10):980–9.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Foley DL, Goldston DB, Costello EJ, Angold A. Proximal psychiatric risk factors for suicidality in youth: the Great Smoky Mountains study. Arch Gen Psychiatry. 2006;63:1017–24.PubMedCrossRefGoogle Scholar
  4. 4.
    Jacobson CM, Muehlenkamp JJ, Miller AL, Turner JB. Psychiatric impairment among adolescents engaging in different types of deliberate self-harm. J Clin Child Adolesc Psychol. 2008;37(2):363–75.PubMedCrossRefGoogle Scholar
  5. 5.
    Beesdo-Baum K, Pine DS, Lieb R, Wittchen J. Mental disorders in adolescence and young adulthood: homotypic and heterotypic longitudinal associations. American College of Neuropsychopharmacology 51st Annual Meeting, Hollywood, Florida, 2012.Google Scholar
  6. 6.
    Pine DS, Cohen P, Gurley D, Brook J, Ma Y. The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. Arch Gen Psychiatry. 1998;55(1):56–64.PubMedCrossRefGoogle Scholar
  7. 7.
    Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008;359(26):2753–66.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Beesdo K, Pine DS, Lieb R, Wittchen H-U. Incidence and risk patterns of anxiety and depressive disorders and categorization of generalized anxiety disorder. Arch Gen Psychiatry. 2010;67(1):47–57.PubMedCrossRefGoogle Scholar
  9. 9.
    Blackford JU, Pine DS. Neural substrates of childhood anxiety disorders: a review of neuroimaging findings. Child Adolesc Psychiatr Clin N Am. 2012;21(3):501–25.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Strawn JR, Wehry AM, DelBello MP, Rynn MA, Strakowski S. Establishing the neurobiologic basis of treatment in children and adolescents with generalized anxiety disorder. Depress Anxiety. 2012;29:328–39.PubMedCrossRefGoogle Scholar
  11. 11.
    Kendall PC, Compton SN, Walkup JT, Birmaher B, Albano AM, Sherrill J, et al. Clinical characteristics of anxiety disordered youth. J Anxiety Disord. 2010;24(3):36–5.CrossRefGoogle Scholar
  12. 12.
    Beesdo K, Knappe S, Pine DS. Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V. Psychiatr Clin N Am. 2009;32:483–524.CrossRefGoogle Scholar
  13. 13.
    Costello EJ, Copeland W, Angold A. Trends in psychopathology across the adolescent years: what changes when children become adolescents, and when adolescents become adults? J Child Psychol Psychiatry. 2011;52(10):1015–25.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.•
    Beesdo-Baum K, Knappe S. Developmental epidemiology of anxiety disorders. Child Adolesc Psychiatr Clin N Am. 2012;21(3):457–78. This paper describes the emergence and trajectory of anxiety disorders over the lifespan in children, adolescents and young adults.PubMedCrossRefGoogle Scholar
  15. 15.
    Bittner A, Egger HL, Erkanli A, Costello EJ, Foley DL, Angold A. What do childhood anxiety disorders predict? J Child Psychol Psychiatry. 2007;48(12):1174–83.PubMedCrossRefGoogle Scholar
  16. 16.
    Copeland WE, Shanahan L, Costello J, Angold A. Childhood and adolescent psychiatric disorders as predictors of young adult disorders. Arch Gen Psychiatry. 2009;66(7):764–72.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Woodward LJ, Fergusson DM. Life course outcomes of young people with anxiety disorders in adolescence. J Am Acad Child Adolesc Psychiatry. 2001;40(9):1086–93.PubMedCrossRefGoogle Scholar
  18. 18.
    Gregory AM, Caspi A, Moffitt TE, Koenen K, Eley TC, Poulton R. Juvenile mental health histories of adults with anxiety disorders. Am J Psychiatry. 2007;164(2):301–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Wittchen H-U, Lieb R, Pfister H, Schuster P. The waxing and waning of mental disorders: evaluating the stability of syndromes of mental disorders in the population. Compr Psychiatry. 2000;41: 2, Suppl 1:122-132.Google Scholar
  20. 20.
    Zimmermann P, Wittchen H-U, Höfler M, Pfister H, Kessler RC, Lieb R. Primary anxiety disorders and the development of subsequent alcohol use disorder: a 4-year community study of adolescents and young adults. Psychol Med. 2003;33(7):1211–22.PubMedCrossRefGoogle Scholar
  21. 21.
    Beesdo K, Bittner A, Pine DS, Stein MB, Hofler M, Lieb R, et al. Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life. Arch Gen Psychiatry. 2007;64(8):903–12.PubMedCrossRefGoogle Scholar
  22. 22.
    Wittchen H-U, Kessler RC, Pfister H, Lieb R. Why do people with anxiety disorders become depressed? A prospective-longitudinal community study. Acta Psychiatr Scand Suppl. 2000;406:14–23.PubMedCrossRefGoogle Scholar
  23. 23.
    Bittner A, Goodwin RD, Wittchen HU, Beesdo K, Hofler M, Lieb R. What characteristics of primary anxiety disorders predict subsequent major depressive disorder? J Clin Psychiatry. 2004;65(5):618–26.PubMedCrossRefGoogle Scholar
  24. 24.
    Shear MK, Bjelland I, Beesdo K, Gloster AT, Wittchen H-U. Supplementary dimensional assessment in anxiety disorders. Int J Methods Psychiatr Res. 2007;16(Suppl1):S52–64.PubMedCrossRefGoogle Scholar
  25. 25.
    Wittchen H-U, Knappe S, Schumann G. The psychological perspective on mental health and mental disorder research: introduction to the ROAMER work package 5 consensus document. Int J Methods Psychiatr Res. 2014;23(S1):15–27.PubMedCrossRefGoogle Scholar
  26. 26.
    Copeland WE, Angold A, Shanahan L, Costello EJ. Longitudinal patterns of anxiety from childhood to adulthood: the Great Smoky Mountains Study. J Am Acad Child Adolesc Psychiatry. 2014;53(1):21–33.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Beesdo-Baum K, Lieb R, Wittchen H-U. Anxiety disorders as early stages of malignant psychopathological long-term outcomes: results of the 10-years prospective EDSP study. Compr Psychiatry. 2013;54(8):e16.CrossRefGoogle Scholar
  28. 28.
    Strawn JR, Dominick KC, Patino LR, Doyle CD, Picard PS, Phan KL. Neurobiology of pediatric anxiety disorders. Curr Behav Neurosci Rep. 2014;1(3):154–60.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Maslowsky J, Mogg K, Bradley BP, McClure-Tone E, Ernst M, Pine DS, et al. A preliminary investigation of neural correlates of treatment in adolescents with generalized anxiety disorder. J Child Adolesc Psychopharmacol. 2010;20(2):105–11.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    McClure EB, Monk CS, Nelson EE, Parrish JM, Adler A, Blair RJ, et al. Abnormal attention modulation of fear circuit function in pediatric generalized anxiety disorder. Arch Gen Psychiatry. 2007;64(1):97–106.PubMedCrossRefGoogle Scholar
  31. 31.
    Strawn JR, Bitter SM, Weber WA, Chu WJ, Whitsel RM, Adler C, et al. Neurocircuitry of generalized anxiety disorder in adolescents: a pilot functional neuroimaging and functional connectivity study. Depress Anxiety. 2012;29(11):939–47.PubMedCrossRefGoogle Scholar
  32. 32.
    American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2007;46:267–83.CrossRefGoogle Scholar
  33. 33.
    March JS, Parker JD, Sullivan K, Stallings P, Conners CK. The Multidimensional Anxiety Scale for Children (MASC): factor structure, reliability, and validity. J Am Acad Child Adolesc Psychiatry. 1997;36(4):554–65.PubMedCrossRefGoogle Scholar
  34. 34.
    Birmaher B, Brent DA, Chiappetta L, Bridge J, Monga S, Baugher M. Psychometric properties of the Screen for Child Anxiety Related Emotional Disorders (SCARED): a replication study. J Am Acad Child Adolesc Psychiatry. 1999;38(10):1230–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Spence SH. A measure of anxiety symptoms among children. Behav Res Ther. 1998;36:545–66.PubMedCrossRefGoogle Scholar
  36. 36.
    Velting ON, Setzer NJ, Albano AM. Update and advances in assessment and cognitive-behavioral treatment of anxiety disorders in children and adolescents. Prof Psychol Res Pract. 2004;35:42–54.CrossRefGoogle Scholar
  37. 37.
    Research Units on Pediatric Psychopharmacology Anxiety Study Group. The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties. J Am Acad Child Adolesc Psychiatry. 2002;41(9):1061–9.CrossRefGoogle Scholar
  38. 38.
    Möller E, Majdandzic M, Craske MG, Bögels S. Dimensional assessment of anxiety disorders in parents and children for DSM-5. Int J Methods Psychiatr Res. 2014;23(3):331–44.PubMedCrossRefGoogle Scholar
  39. 39.
    Beidel DC, Turner SM, Sallee FR, Ammerman RT, Crosby LA, Pathak S. SET-C versus fluoxetine in the treatment of childhood social phobia. J Am Acad Child Adolesc Psychiatry. 2007;46(12):1622–32.PubMedCrossRefGoogle Scholar
  40. 40.•
    Piacentini J, Bennett S, Compton SN, Kendall PC, Birmaher B, Albano AM, et al. 24- and 36-week outcomes for the Child/Adolescent Anxiety Multimodal Study (CAMS). J Am Acad Child Adolesc Psychiatry. 2014;53:297–310. This analyses describes long-term outcomes following an acute, double-blind, placebo-controlled trial of sertraline, CBT or sertraline + CBT.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Ginsburg GS, Becker EM, Keeton CP, Sakolsky D, Piacentini J, Albnano AM, et al. Naturalistic follow-up of youths treated for pediatric anxiety disorders. JAMA Psychiatry. 2014;71(3):310–8.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Hirschfeld-Becker DR, Masek B, Henin A, Blakely LR, Pollock-Wurman RA, McQuade J, et al. Cognitive behavioral therapy for 4- to 7-year-old children with anxiety disorders: a randomized clinical trial. J Consult Clin Psychol. 2010;78(4):498–510.CrossRefGoogle Scholar
  43. 43.
    Zgierska A, Rabago D, Chawla N, Kushner K, Koehler R, Marlatt A. Mindfulness meditation for substance use disorders: a systematic review. Subst Abus. 2009;30(4):266–94.PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Burke CA. Mindfulness-based approaches with children and adolescents: a preliminary review of current research in an emergent field. J Child Fam Stud. 2010;19(2):133–44.CrossRefGoogle Scholar
  45. 45.
    Kim YW, Lee SH, Choi TK, Suh SY, Kim B, Kim CM, et al. Effectiveness of mindfulness‐based cognitive therapy as an adjuvant to pharmacotherapy in patients with panic disorder or generalized anxiety disorder. Depress Anxiety. 2009;26(7):601–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Hoge EA, Bui E, Marques L, Metcalf CA, Morris LK, Robinaugh DJ, et al. Randomized controlled trial of mindfulness meditation for generalized anxiety disorder: effects on anxiety and stress reactivity. J Clin Psychiatry. 2013;74(8):786–92.PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Koszycki D, Benger M, Shlik J, Bradwejn J. Randomized trial of a meditation-based stress reduction program and cognitive behavior therapy in generalized social anxiety disorder. Behav Res Ther. 2007;45(10):2518–26.PubMedCrossRefGoogle Scholar
  48. 48.
    Jazaieri H, Goldin PR, Werner K, Ziv M, Gross JJ. A randomized trial of MBSR versus aerobic exercise for social anxiety disorder. J Clin Psychol. 2012;68(7):715–31.PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Bögels SM, Sijbers GFVM, Voncken M. Mindfulness and task concentration training for social phobia: a pilot study. J Cogn Psychother. 2006;20(1):33–44.CrossRefGoogle Scholar
  50. 50.
    Cassin SE, Rector NA. Mindfulness and the attenuation of post-event processing in social phobia: an experimental investigation. Cogn Behav Ther. 2011;40(4):267–78.PubMedCrossRefGoogle Scholar
  51. 51.
    Hooper N, Davies N, Davies L, McHugh L. Comparing thought suppression and mindfulness as coping techniques for spider fear. Conscious Cogn. 2011;20(4):1824–30.PubMedCrossRefGoogle Scholar
  52. 52.
    Vøllestad J, Sivertsen B, Nielsen GH. Mindfulness-based stress reduction for patients with anxiety disorders: evaluation in a randomized controlled trial. Behav Res Ther. 2011;49(4):281–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Arch JJ, Ayers CR, Baker A, Almklov E, Dean DJ, Craske MG. Randomized clinical trial of adapted mindfulness-based stress reduction versus group cognitive behavioral therapy for heterogeneous anxiety disorders. Behav Res Ther. 2013;51(4):185–96.PubMedCrossRefGoogle Scholar
  54. 54.
    Kocovski NL, Fleming JE, Hawley LL, Huta V, Antony MM. Mindfulness and acceptance-based group therapy versus traditional cognitive behavioral group therapy for social anxiety disorder: a randomized controlled trial.". Behav Res Ther. 2013;51(12):889–98.PubMedCrossRefGoogle Scholar
  55. 55.
    Catani C, Kohiladevy M, Ruf M, Schauer E, Elbert T, Neuner F. Treating children traumatized by war and Tsunami: a comparison between exposure therapy and meditation-relaxation in North-East Sri Lanka. BMC Psychiatry. 2009;9:22.PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Liehr P, Diaz N. A pilot study examining the effect of mindfulness on depression and anxiety for minority children. Arch Psychiatr Nurs. 2010;24(1):69–71.PubMedCrossRefGoogle Scholar
  57. 57.
    Göttken T, White LO, Klein AM, von Klitzing K. Short-term psychoanalytic child therapy for anxious children: a pilot study. Psychotherapy (Chic). 2014;51(1):148–58.CrossRefGoogle Scholar
  58. 58.
    Fonagy P, Target M. Predictors of outcome in child psychoanalysis: a retrospective study of 763 cases at the Anna Freud Centre. J Am Psychoanal Assoc. 1996;44(1):27–77.PubMedGoogle Scholar
  59. 59.
    Kiser RS, Lebovitz RM. Monoaminergic mechanisms in aversive brain stimulation. Physiol Behav. 1975;15(1):47–53.PubMedCrossRefGoogle Scholar
  60. 60.
    Birmaher B, Axelson DA, Monk K, Kalas C, Clark DB, Ehmann M, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2003;42(4):415–23.PubMedCrossRefGoogle Scholar
  61. 61.
    Research Units on Pediatric Psychopharmacology Anxiety Study Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med. 2001;344(17):1279–85.CrossRefGoogle Scholar
  62. 62.
    Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P, et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry. 2004;61(11):1153–62.PubMedCrossRefGoogle Scholar
  63. 63.
    Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry. 2001;158(12):2008–14.PubMedCrossRefGoogle Scholar
  64. 64.
    Rynn MA, Riddle MA, Yeung PP, Kunz NR. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am J Psychiatry. 2007;164(2):290–300.PubMedCrossRefGoogle Scholar
  65. 65.
    March JS, Entusah AR, Rynn M, Albano AM, Tourian KA. A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry. 2007;62(10):1149–54.PubMedCrossRefGoogle Scholar
  66. 66.•
    Strawn JR, Prakash A, Zhang Q, Pangallo BA, Stroud CE, Cai N, Findling RL. A randomized, placebo-controlled study of duloxetine for the treatment of children (7-11 years) and adolescents (12-17 years) with generalized anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2015;54(4):283–93. This recent article describes the registration trial for the only USFDA approved antidepressant for GAD in children and adolescents.Google Scholar
  67. 67.•
    Strawn JR, Welge JA, Wehry AM, Keeshin B, Rynn MA. Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. Depress Anxiety. 2015;32(3):149–57. This article represents the only meta-analysis of antidepressants in pediatric patients with non-OCD anxiety disorders and also examines treatment-emergent side effect profiles.PubMedCrossRefGoogle Scholar
  68. 68.
    Simeon JG, Ferguson HB, Knott V, Roberts N, Gauthier B, Dubois C, et al. Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. J Am Acad Child Adolesc Psychiatry. 1992;31(1):29–33.PubMedCrossRefGoogle Scholar
  69. 69.
    Graae F, Milner J, Rizzotto L, Klein RG. Clonazepam in childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 1994;33(3):372–6.PubMedCrossRefGoogle Scholar
  70. 70.
    Geller D, Donnelly C, Lopez F, Rubin R, Newcorn J, Sutton V, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(9):1119–27.PubMedCrossRefGoogle Scholar
  71. 71.
    Ginsburg GS, Kendall PC, Sakolsky D, Compton SN, Piacentini J, Albano AM, et al. Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS. J Consult Clin Psychol. 2011;79(6):806–13.PubMedCentralPubMedCrossRefGoogle Scholar
  72. 72.
    Masi G, Pfanner C, Mucci M, Berloffa S, Magazu A, Parolin G, et al. Pediatric social anxiety disorder: predictors of response to pharmacological treatment. J Child Adolesc Psychopharmacol. 2012;22(6):410–4.PubMedCrossRefGoogle Scholar
  73. 73.•
    Compton SN, Peris TS, Almirall D, Birmaher B, Sherrill J, Kendall PC, et al. Predictors and moderators of treatment response in childhood anxiety disorders: results from the CAMS trial. J Consult Clin Psychol. 2014;82(2):212–24. A recent analysis of clinical and demographic factors which are associated with differential response to psychopharmacologic and psychotherapeutic response in pediatric patients with anxiety disorders.PubMedCentralPubMedCrossRefGoogle Scholar
  74. 74.
    Gittelman-Klein R, Klein DF. Controlled imipramine treatment of social phobia. Arch Gen Psychiatry. 1971;25(3):204–7.CrossRefGoogle Scholar
  75. 75.
    Klein RG, Koplewicz HS, Kanner A. Imipramine treatment of children with separation anxiety disorder. J Am Acad Child Adolesc Psychiatry. 1992;31(1):21–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Bernstein GA, Borchardt CM, Perwien AR, Crosby RD, Kushner MG, Thuras PD, et al. Imipramine plus cognitive-behavioral therapy in the treatment of school refusal. J Am Acad Child Adolesc Psychiatry. 2000;39(3):276–83.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Anna M. Wehry
    • 1
  • Katja Beesdo-Baum
    • 2
  • Meghann M. Hennelly
    • 3
  • Sucheta D. Connolly
    • 3
  • Jeffrey R. Strawn
    • 1
    • 4
    Email author
  1. 1.College of Medicine, Department of Psychiatry and Behavioral NeuroscienceUniversity of CincinnatiCincinnatiUSA
  2. 2.Institute of Clinical Psychology and Psychotherapy, Department of Psychology, Faculty of ScienceTechnische UniversityDresdenGermany
  3. 3.Department of PsychiatryUniversity of Illinois at ChicagoChicagoUSA
  4. 4.Department of PsychiatryCincinnati Children’s Hospital Medical CenterCincinnatiUSA

Personalised recommendations